Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.66 |
| ▸ | KLK1 | P06870 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 7/20 | 0.60 |
| ▸ | F2 | P00734 | 6/20 | 0.60 |
| ▸ | PLAT | P00750 | 6/20 | 0.60 |
| ▸ | PLG | P00747 | 6/20 | 0.56 |
| ▸ | KLK8 | O60259 | 5/20 | 0.56 |
| ▸ | KLK4 | Q9Y5K2 | 5/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.56 |
| ▸ | KLK2 | P20151 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436931 | 0.83 | POLB (0.52) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL5689257 | 0.82 | ELANE (0.77) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL7403534 | 0.81 | F2 (0.86) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL9970972 | 0.80 | ELANE (1.00) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL5881673 | 0.80 | ELANE (0.70) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL9971041 | 0.78 | PLAU (0.75) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL7405303 | 0.76 | CTRB1 (0.55) | ELANE | |
| SCHEMBL17126245 | 0.76 | KLK1 (0.83) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL12942620 | 0.75 | KYNU (0.55) | ELANEKLK1TP53PLAUF2 | |
| SCHEMBL22118319 | 0.75 | CTRB1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295082-B1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS PHARMA ASS (GB) | 2013-09-18 | — | — | EP | disclosed |
| EP-1394261-B1 | ANTIGENS FOR IMMUNISATION | FDS PHARMA ASS (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2295082-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma Ass. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-7560529-B2 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | FDS Pharma (GB) | 2009-07-14 | — | — | US | disclosed |
| WO-2008078177-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNIZATION AND NUCLEOTIDE SEQUENCE | FDS PHARMA ASS. (RU) | 2008-07-03 | — | — | WO | disclosed |
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | LIFEBIO LABORATORIES LLC | 2007-08-02 | — | — | US | disclosed |
| US-20040265975-A1 | glycoprotein 120; fusion proteins; myelin basic protein; autoimmune diseases; genetic vaccines | FDS PHARMA ASS. (GB) | 2004-12-30 | — | — | US | disclosed |
| EP-1394261-A2 | METHOD FOR PRODUCING CATALYTIC ANTIBODIES (VARIANTS), ANTIGENS FOR IMMUNISATION AND NUCLEOTIDE SEQUENCE | ASGL - Farmatsevticjeskie Innovatsii, Zaptryote Aktsionernoe Obschestvo (RU) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070178109-A1 | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence | SSB, DNMT3L, NASP | ELANE 1518/4885KLK1 812/4885TP53 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.